- Chemed Corporation (CHE, Financial) reports a 9.8% increase in revenue, reaching $646.9 million for Q1 2025.
- GAAP Diluted EPS rose by 14.6% to $4.86; Adjusted Diluted EPS increased by 8.3% to $5.63.
- VITAS Healthcare shows strong growth with a 15.1% rise in net patient revenue to $407.4 million.
Chemed Corporation (CHE), a leading provider of end-of-life care and plumbing services, announced its financial results for the first quarter ending March 31, 2025. The company's consolidated revenue surged by 9.8%, reaching $646.9 million compared to the same period last year. This growth was driven in part by their subsidiary, VITAS Healthcare Corporation, which reported net patient revenue of $407.4 million, a notable increase of 15.1%.
The company's earnings performance was robust, with GAAP Diluted Earnings-per-Share (EPS) rising by 14.6% to $4.86. Adjusted Diluted EPS saw an 8.3% increase, reaching $5.63.
VITAS Healthcare, one of the largest providers of end-of-life care in the U.S., demonstrated significant growth as its Average Daily Census (ADC) increased by 13.1% to 22,244. The segment also saw admissions rise by 7.3% to 18,139, contributing to a net income of $50.0 million, an increase of 13.8% when excluding certain discrete items.
Roto-Rooter, the other major segment of Chemed, reported more modest growth with revenues inching up by 1.8% to $239.5 million. However, this segment faced challenges, with net income down by 2.1%, and Adjusted EBITDA declined by 2.4% to $59.2 million.
Despite these challenges, Chemed maintains a strong financial position with cash and cash equivalents of $173.9 million and no current or long-term debt as of March 31, 2025. The company repurchased 50,000 shares for $29.8 million during the quarter, leaving $225.6 million remaining in the share repurchase authorization.
Chemed plans to provide updated earnings guidance for 2025 in its June earnings release. The company will discuss these results further during a conference call scheduled for April 24, 2025.
